divarasib   Click here for help

GtoPdb Ligand ID: 11963

Synonyms: GDC-6036 | GDC6036 | RG-6330 | RG6330
Compound class: Synthetic organic
Comment: GDC-6036 is an oral, covalent inhibitor that targets oncogenic KRASG12C [2-3]. Inhibitor binding locks KRASG12C into its inactive GDP-bound state. GDC-6036's chemical structure was revealed at the AACR spring meeting in 2022. The structure is claimed i patent US11236068B2 [1], and [3] provides the chemical name 1-((S)-4-((R)-7-(6-Amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1- methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one (adipiate salt). We matched GDC-6036's chemical structure to the INN 'divarasib' which was published in the WHO's proposed INN list 127 on 21 July 2022.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 100.71
Molecular weight 621.22
XLogP 6.2
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)N1CCN([C@H](C1)C)c1nc(OC[C@@H]2CCCN2C)nc2c1cc(Cl)c(c2F)c1nc(N)cc(c1C(F)(F)F)C
Isomeric SMILES C[C@H]1CN(CCN1c1c2cc(Cl)c(c(F)c2nc(OC[C@@H]2CCCN2C)n1)c1c(c(C)cc(N)n1)C(F)(F)F)C(=O)C=C
InChI InChI=1S/C29H32ClF4N7O2/c1-5-21(42)40-9-10-41(16(3)13-40)27-18-12-19(30)22(26-23(29(32,33)34)15(2)11-20(35)36-26)24(31)25(18)37-28(38-27)43-14-17-7-6-8-39(17)4/h5,11-12,16-17H,1,6-10,13-14H2,2-4H3,(H2,35,36)/t16-,17-/m0/s1
InChI Key ZRBPIAWWRPFDPY-IRXDYDNUSA-N
No information available.
Summary of Clinical Use Click here for help
GDC-6036 will be evaluated for efficacy in advanced KRASG12C positive solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04449874 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Phase 1 Interventional Genentech, Inc.
NCT03178552 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) Phase 2/Phase 3 Interventional Hoffmann-La Roche